The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma
A phase 2 trial of Pembrolizumab in melanoma, run by Primmune Therapeutics, Inc., now recruiting.
Overview
The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma is a phase 2 interventional study registered as NCT07565285 by Primmune Therapeutics, Inc., with 48 participants planned, started 2026-07-01 and due to reach its primary completion in 2027-12. Interventions recorded: PRTX007, Pembrolizumab. Conditions listed: Melanoma Stage III. No results are recorded here; the registry entry is the source.
Setting
A Phase 2 Study to Investigate the Activity of Neoadjuvant PRTX007 Combined With Pembrolizumab in Participants With Stage III Melanoma (INFLECTION-003)
Phase
Phase 2
Sponsor
Primmune Therapeutics, Inc.
Registry
Enrolled
48